This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator. Nitric oxide (NO) is decreased in the airways of persons with cystic fibrosis (CF). Inhaled NO has the potential to be an effective treatment in CF lung disease, especially because of its anti-inflammatory and antimicrobial activities. The main objective of this initial project is to evaluate the safety and tolerability of inhaled NO over a 2 day period in older children and adults with CF. The long term objectives are to determine whether inhaled NO may be a useful therapeutic strategy for CF patients during an acute pulmonary exacerbation or even as a chronic therapy in CF patients with severe lung disease.
Showing the most recent 10 out of 837 publications